MDMA Statement on Introduction of the "STRONG Patents Act"

Legislation provides a balanced, targeted approach to end abuse, support innovation

Washington, D.C. – Mark Leahey, President and CEO of the Medical Device Manufacturers Association (MDMA), issued the following statement today regarding legislation introduced in the Senate, the “STRONG Patents Act,” which is designed to thwart frivolous patent lawsuits while leveling the playing field for inventors:

“MDMA applauds the introduction of the ‘STRONG Patents Act' for its measured approach to address issues facing our nation’s patent system. We commend the leadership of Senator Coons for his support of entrepreneurs and start-ups across America's innovation ecosystem.

“While MDMA supports efforts to deal with patent litigation abuse, we must ensure that any legislation to address this problem does not have the unintended consequences of weakening one's patent rights. The ‘STRONG Patents Act’ targets the concerns of patent holders to end abusive practices, while establishing balance in post-grant proceedings at the PTO and eliminating fee diversion.

“A vibrant and strong patent system is the cornerstone of U.S. innovation, and all stakeholders must continue working together to maintain this delicate balance to protect inventors and future economic growth. MDMA looks forward to working with Senator Coons and all elected officials to ensure America's innovation economy remains the envy of the world.”